204 related articles for article (PubMed ID: 15831699)
41. Genomic structure and promoter region of the murine Janus-family tyrosine kinase, Jak3.
Gurniak CB; Thomis DC; Berg LJ
DNA Cell Biol; 1997 Jan; 16(1):85-94. PubMed ID: 9022047
[TBL] [Abstract][Full Text] [Related]
42. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis.
McTigue MA; Wickersham JA; Pinko C; Showalter RE; Parast CV; Tempczyk-Russell A; Gehring MR; Mroczkowski B; Kan CC; Villafranca JE; Appelt K
Structure; 1999 Mar; 7(3):319-30. PubMed ID: 10368301
[TBL] [Abstract][Full Text] [Related]
43. Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ; Husa M; Li D; Hofmann SR; Watford W; Roberts JL; Buckley RH; Changelian P; Candotti F
Mol Immunol; 2004 Jul; 41(6-7):727-37. PubMed ID: 15220007
[TBL] [Abstract][Full Text] [Related]
44. The role of Jak3 in lymphoid development, activation, and signaling.
Thomis DC; Berg LJ
Curr Opin Immunol; 1997 Aug; 9(4):541-7. PubMed ID: 9287175
[TBL] [Abstract][Full Text] [Related]
45. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
Notarangelo LD; Mella P; Jones A; de Saint Basile G; Savoldi G; Cranston T; Vihinen M; Schumacher RF
Hum Mutat; 2001 Oct; 18(4):255-63. PubMed ID: 11668610
[TBL] [Abstract][Full Text] [Related]
46. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model.
Notarangelo LD; Giliani S; Mella P; Schumacher RF; Mazza C; Savoldi G; Rodriguez-Pérez C; Badolato R; Mazzolari E; Porta F; Candotti F; Ugazio AG
Immunobiology; 2000 Aug; 202(2):106-19. PubMed ID: 10993286
[TBL] [Abstract][Full Text] [Related]
47. Peripheral expression of Jak3 is required to maintain T lymphocyte function.
Thomis DC; Berg LJ
J Exp Med; 1997 Jan; 185(2):197-206. PubMed ID: 9016869
[TBL] [Abstract][Full Text] [Related]
48. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice.
Suzuki K; Nakajima H; Saito Y; Saito T; Leonard WJ; Iwamoto I
Int Immunol; 2000 Feb; 12(2):123-32. PubMed ID: 10653847
[TBL] [Abstract][Full Text] [Related]
49. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Fujitani Y; Hibi M; Fukada T; Takahashi-Tezuka M; Yoshida H; Yamaguchi T; Sugiyama K; Yamanaka Y; Nakajima K; Hirano T
Oncogene; 1997 Feb; 14(7):751-61. PubMed ID: 9047382
[TBL] [Abstract][Full Text] [Related]
50. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases.
Takahashi T; Shirasawa T
FEBS Lett; 1994 Apr; 342(2):124-8. PubMed ID: 8143863
[TBL] [Abstract][Full Text] [Related]
51. Revised exon-intron structure of human JAK3 locus.
Brooimans RA; van der Slot AJ; van den Berg AJ; Zegers BJ
Eur J Hum Genet; 1999; 7(7):837-40. PubMed ID: 10573019
[TBL] [Abstract][Full Text] [Related]
52. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells.
Verbsky JW; Bach EA; Fang YF; Yang L; Randolph DA; Fields LE
J Biol Chem; 1996 Jun; 271(24):13976-80. PubMed ID: 8662778
[TBL] [Abstract][Full Text] [Related]
53. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
54. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Liongue C; Ratnayake T; Basheer F; Ward AC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474223
[TBL] [Abstract][Full Text] [Related]
55. Crystal Structure of the FERM-SH2 Module of Human Jak2.
McNally R; Toms AV; Eck MJ
PLoS One; 2016; 11(5):e0156218. PubMed ID: 27227461
[TBL] [Abstract][Full Text] [Related]
56. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain.
Hall T; Emmons TL; Chrencik JE; Gormley JA; Weinberg RA; Leone JW; Hirsch JL; Saabye MJ; Schindler JF; Day JE; Williams JM; Kiefer JR; Lightle SA; Harris MS; Guru S; Fischer HD; Tomasselli AG
Protein Expr Purif; 2010 Jan; 69(1):54-63. PubMed ID: 19781647
[TBL] [Abstract][Full Text] [Related]
57. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.
Williams JC; Weijland A; Gonfloni S; Thompson A; Courtneidge SA; Superti-Furga G; Wierenga RK
J Mol Biol; 1997 Dec; 274(5):757-75. PubMed ID: 9405157
[TBL] [Abstract][Full Text] [Related]
58. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
59. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
60. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.
Kirken RA; Erwin RA; Taub D; Murphy WJ; Behbod F; Wang L; Pericle F; Farrar WL
J Leukoc Biol; 1999 Jun; 65(6):891-9. PubMed ID: 10380915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
